Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard has earned a coveted five-star ranking.
With that in mind, let's take a closer look at C.R. Bard and see what CAPS investors are saying about the stock right now.
C.R. Bard facts
Murray Hill, N.J. (1907)
Health care equipment
Chairman/CEO Timothy Ring
Return on Equity (average, past 3 years)
$809.1 million / $1.3 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 274 members who have rated C.R. Bard believe the stock will outperform the S&P 500 going forward.
A couple of weeks ago, one of those Fools, All-Star DrGoldin, succinctly summed up the C.R. Bard bull case for our community: "They're profitable. They're CONSISTENTLY profitable. They're in a sector that can only improve. The price is reasonable. What's not to like?"
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its four-star rating, C.R. Bard may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why C.R. Bard Is Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson and Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.